Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

GMP Tablet Production for Clinical Trials Commences

181113_GMP Tablet Manufacture_44070bgt7qng63

Category: News & Announcements 2018By Richard Mollard November 13, 2018

Related posts

Top 20 Shareholders 30th December 2018
January 7, 2019

Top 20 Shareholders 14 December 2018
December 17, 2018

PharmAust Manufacturing Method Maintains Drug Potency
December 2, 2018

2018 AGM Results
November 9, 2018

2018 AGM Presentation
November 9, 2018

Top 20 Shareholders 31st October 2018
November 6, 2018

Recent Articles

200921_PharmAust Awarded FightMND Grant for Phase I Trial
September 21, 2020
14 September, Shareholder Update
September 14, 2020
Elanco not to Exercise Agreed Option
September 9, 2020
Monepantel Anti-Covid-19 Activity Confirmed
September 9, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

The Market Herald @themarketherald·

PharmAust (PAA) has been granted $881,085 for a phase one clinical trial of monepantel in patients with Motor Neurone Disease (MND).
--
https://buff.ly/32Nvu44

#themarketherald #asxnews #asx #asx200 #asxtoday #ausstocks #ausbiz $PAA $PAA.AX

Reply on Twitter 1307920108770164736 Retweet on Twitter 13079201087701647362 Like on Twitter 13079201087701647363 Twitter 1307920108770164736

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions